CytomX Therapeutics Reports Exit/Disposal Costs
Ticker: CTMX · Form: 8-K · Filed: Jan 6, 2025 · CIK: 1501989
| Field | Detail |
|---|---|
| Company | Cytomx Therapeutics, INC. (CTMX) |
| Form Type | 8-K |
| Filed Date | Jan 6, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.00001, $5 million, $6 m |
| Sentiment | neutral |
Sentiment: neutral
Topics: restructuring, disposal
TL;DR
CytomX is shedding some costs, but details are scarce.
AI Summary
CytomX Therapeutics, Inc. filed an 8-K on January 6, 2025, to report on cost associated with exit or disposal activities. The filing does not contain specific dollar amounts or details regarding the nature of these exit or disposal activities.
Why It Matters
This filing indicates potential restructuring or discontinuation of certain operations within CytomX Therapeutics, which could impact future financial performance and strategic direction.
Risk Assessment
Risk Level: medium — The filing indicates costs associated with exit or disposal activities, suggesting potential restructuring or operational changes that carry inherent business risks.
Key Players & Entities
- CytomX Therapeutics, Inc. (company) — Registrant
- January 6, 2025 (date) — Date of earliest event reported
FAQ
What specific activities are associated with the exit or disposal costs reported by CytomX Therapeutics?
The filing does not specify the nature of the exit or disposal activities.
What is the total dollar amount of the costs associated with exit or disposal activities?
The filing does not disclose a specific dollar amount for these costs.
When did the exit or disposal activities occur or become effective?
The filing reports costs associated with exit or disposal activities as of January 6, 2025.
Is this filing related to a specific product or program discontinuation?
The filing does not provide details on whether the costs are related to specific products or programs.
What is the primary business of CytomX Therapeutics, Inc.?
CytomX Therapeutics, Inc. is in the Pharmaceutical Preparations industry (SIC code 2834).
Filing Stats: 909 words · 4 min read · ~3 pages · Grade level 14.7 · Accepted 2025-01-06 16:10:52
Key Financial Figures
- $0.00001 — nge on which registered Common Stock, $0.00001 par value per share CTMX Nasdaq Glo
- $5 million — restructuring charges of approximately $5 million to $6 million, which the Company expect
- $6 m — charges of approximately $5 million to $6 million, which the Company expects will b
Filing Documents
- d909597d8k.htm (8-K) — 26KB
- 0001193125-25-002165.txt ( ) — 150KB
- ctmx-20250106.xsd (EX-101.SCH) — 3KB
- ctmx-20250106_lab.xml (EX-101.LAB) — 18KB
- ctmx-20250106_pre.xml (EX-101.PRE) — 11KB
- d909597d8k_htm.xml (XML) — 4KB
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by terminology such as "aim," "anticipate," "assume," "believe," "contemplate," "continue," "could," "design," "due," "estimate," "expect," "goal," "intend," "may," "objective," "plan," "positioned," "potential," "predict," "seek," "should," "suggest," "target," "on track," "will," "would" and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. All statements other than statements of historical facts contained in this Current Report on Form 8-K are forward-looking statements. These forward-looking statements include, but are not limited to, statements about: the percentage reduction in organizational headcount; the timing of completion of the workforce reduction; the Company's expectations regarding the cash runway; and the Company's estimates regarding the amount and timing of restructuring charges and cash payments related to restructuring charges. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated. These and other risks are described in under the section titled "Risk Factors" contained in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 7, 2024, and the Company's other filings with the Securities and Exchange Commission. Any forward-looking statements that the Company makes in this Current Report on Form 8-K are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this Current Report on Form 8-K. Except as required by la
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 6, 2025 CYTOMX THERAPEUTICS, INC. By: /s/ Lloyd Rowland Lloyd Rowland Senior Vice President, General Counsel